| Code # |
Active Pharmaceutical Ingredient |
Dosage Form |
Development Stage |
Key Points |
| BS-102 |
Docetaxel trihydrate
(Cytotoxic anticancer drug) |
IV powder |
Preclinical |
- Non-toxic excipients ⇒ Toxicity ↓
- Selected as a promising cancer nanomedicine candidate by NCL (Nanotechnology Characterization Laboratory) ⇒ PK test in progress by NCL in the United States
|
| BS-104 |
Sorafenib tosylate
(Targeted anticancer drug) |
Tablet |
Clinical |
- Avoidance of infringement of existing patents related to crystal form & formulation
- Bioavailability ↑ & Dose ↓ ⇒ Unabsorbed drug particles in the gut ↓ ⇒ Toxicity ↓
- Phase I clinical trial (pilot study) completed in South Korea
- Planning to conduct a Phase 1 clinical trial (bioequivalence study) in 2020
|
| BS-112 |
Rivaroxaban
(Anticoagulant drug) |
Tablet |
Clinical |
- Bioavailability at fasted state ↑ ⇒ Food effect ↓ ⇒ Patient convenience ↑
|
